Skip to main content
. Author manuscript; available in PMC: 2014 Jan 1.
Published in final edited form as: J Mol Med (Berl). 2012 Oct 24;91(1):25–36. doi: 10.1007/s00109-012-0968-y

Figure 7. Blockade of TRAIL-induced lysosome fusion with plasma membrane in ASM-deficient CAECs.

Figure 7

CAECs were first loaded with FM1–43, a lysosome specific fluorescence probe, and then incubated in fresh medium containing bromide phenol blue (BPB), which reversibly quench FM1–43 fluorescence. In quenching experiments, lysosome fusion with the plasma membrane will allow BPB to enter the lysosomes to quench FM1–43 fluorescence. (A) Left panel: representative confocal fluorescence images of FM1–43 fluorescence in Smpd1+/+ CAECs before and after treatment with TRAIL. Right panel: representative traces of TRAIL-induced changes of FM1–43 fluorescence, normalized to that obtained before TRAIL treatment. (B) Left panel: representative confocal fluorescence images of FM1–43 fluorescence quenching in Smpd1−/− CAECs treated with TRAIL. Right panel: representative traces of TRAIL-induced changes of FM1–43 fluorescence in Smpd1−/− CAECs. (C) Summarized data showing the effect of TRAIL on FM1–43 fluorescence quenching in Smpd1+/+ and Smpd1−/− CAECs. *P<0.05 vs. Smpd1+/+ control (n=6); #P < 0.05 vs. Smpd1+/+ TRAIL (n=6).